EHT
MCID: HYP595
MIFTS: 86

Hypertension, Essential (EHT)

Categories: Cancer diseases, Cardiovascular diseases, Genetic diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypertension, Essential

MalaCards integrated aliases for Hypertension, Essential:

Name: Hypertension, Essential 57
Essential Hypertension 11 42 75 73 28 53 5 43 14 71 33
Hypertension 57 11 42 75 43 14 38 16
High Blood Pressure 42 41 2 63 33
Hypertension, Essential, Susceptibility to 57 5 38
Hypertensive Disease 11 14 71
Primary Hypertension 11 42 33
Hypertension, Salt-Sensitive Essential, Susceptibility to 57 5
Idiopathic Hypertension 11 33
Hypertensive Disorder 28 5
Hyperpiesia 11 33
Eht 57 73
Hypertension, Essential, Susceptibility to, 1 57
Hypertension, Essential, Susceptibility to, 2 57
Hypertension, Essential, Susceptibility to, 3 57
Hypertension, Essential, Susceptibility to, 4 57
Hypertension, Essential, Susceptibility to, 5 57
Hypertension, Essential, Susceptibility to, 6 57
Hypertension, Essential, Salt-Sensitive 57
Systemic Arterial Hypertensive Disorder 33
Hypertension, Salt-Sensitive Essential 57
Systemic Primary Arterial Hypertension 33
Hypertensive Vascular Degeneration 33
Hypertension, Susceptibility to 57
Vascular Hypertensive Disorder 11
Systemic Arterial Hypertension 33
Hypertensive Vascular Disease 33
Primary Htn - [hypertension] 33
High Blood Pressure Disorder 33
Hbp - [high Blood Pressure] 33
Cardiovascular Hypertension 33
Hypertension, Essential 1 57
Hypertension, Essential 2 57
Hypertension, Essential 3 57
Hypertension, Essential 4 57
Hypertension, Essential 5 57
Hypertension, Essential 6 57
Arterial Hypertension Nos 33
Cholesterol Hypertension 33
Elevated Blood Pressure 33
Malignant Hypertension 33
Systemic Hypertension 33
Vascular Hypertension 33
Raised Blood Pressure 33
High Arterial Tension 33
Htn - [hypertension] 33
Benign Hypertension 33
Ht - [hypertension] 33
Hypertension Nos 33
Cholesterol Htn 33
Idiopathic Htn 33
Malignant Htn 33
Vascular Htn 33
Artery Htn 33
Benign Htn 33
Htn 11

Characteristics:


Inheritance:

Multifactorial 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
multiple genes influence susceptibility to hypertension. candidate genes include angiotensinogen (agt, ), angiotensin receptor-1 (agtr1, ), and beta-3 subunit of guanine nucleotide-binding protein (gnb3, ). susceptibility loci include hyt1 and hyt2 .


Classifications:



External Ids:

Disease Ontology 11 DOID:10763 DOID:10825
OMIM® 57 145500
ICD9CM 34 401 401-405.99
NCIt 49 C3117 C3478
SNOMED-CT 68 194757006 38341003
ICD10 31 I10 I10-I15
MedGen 40 C0085580
UMLS 71 C0020538 C0085580

Summaries for Hypertension, Essential

MedlinePlus: 41 What is blood pressure? Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your heart beats, pumping the blood. This is called systolic pressure. When your heart is at rest, between beats, your blood pressure falls. This is called diastolic pressure. Your blood pressure reading uses these two numbers. Usually the systolic number comes before or above the diastolic number. For example, 120/80 means a systolic of 120 and a diastolic of 80. How is high blood pressure diagnosed? High blood pressure usually has no symptoms. So the only way to find out if you have it is to get regular blood pressure checks from your health care provider. Your provider will use a gauge, a stethoscope or electronic sensor, and a blood pressure cuff. He or she will take two or more readings at separate appointments before making a diagnosis. Blood Pressure Category Systolic Blood Pressure Diastolic Blood Pressure Normal Less than 120 and Less than 80 High Blood Pressure (no other heart risk factors) 140 or higher or 90 or higher High Blood Pressure (with other heart risk factors, according to some providers) 130 or higher or 80 or higher Dangerously high blood pressure - seek medical care right away 180 or higher and 120 or higher For children and teens, the health care provider compares the blood pressure reading to what is normal for other kids who are the same age, height, and sex. What are the different types of high blood pressure? There are two main types of high blood pressure: primary and secondary high blood pressure.: Primary, or essential, high blood pressure is the most common type of high blood pressure. For most people who get this kind of blood pressure, it develops over time as you get older. Secondary high blood pressure is caused by another medical condition or use of certain medicines. It usually gets better after you treat that condition or stop taking the medicines that are causing it. Why do I need to worry about high blood pressure? When your blood pressure stays high over time, it causes the heart to pump harder and work overtime, possibly leading to serious health problems such as heart attack, stroke, heart failure, and kidney failure. What are the treatments for high blood pressure? Treatments for high blood pressure include heart-healthy lifestyle changes and medicines. You will work with your provider to come up with a treatment plan. It may include only the lifestyle changes. These changes, such as heart-healthy eating and exercise, can be very effective. But sometimes the changes do not control or lower your high blood pressure. Then you may need to take medicine. There are different types of blood pressure medicines. Some people need to take more than one type. If your high blood pressure is caused by another medical condition or medicine, treating that condition or stopping the medicine may lower your blood pressure. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary: Hypertension, Essential, also known as essential hypertension, is related to pulmonary hypertension and renovascular hypertension, and has symptoms including tremor, angina pectoris and chest pain. An important gene associated with Hypertension, Essential is PTGIS (Prostaglandin I2 Synthase), and among its related pathways/superpathways are Development Angiotensin activation of ERK and ACE Inhibitor Pathway, Pharmacodynamics. The drugs Digoxin and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and eye, and related phenotypes are elevated systolic blood pressure and elevated diastolic blood pressure

MedlinePlus Genetics: 42 Hypertension is abnormally high blood pressure in the arteries, which are the blood vessels that carry blood from the heart to the rest of the body. As the heart beats, it forces blood through the arteries to deliver nutrients and oxygen to the rest of the body. The strength of the blood pushing against the artery walls is blood pressure, which is measured in units called millimeters of mercury (mmHg). The top number in a blood pressure reading is the pressure when the heart pumps (systolic blood pressure), and the bottom number is the pressure between heart beats (diastolic blood pressure). In adults, a normal blood pressure measurement is about 120/80 mmHg. Blood pressure is considered high when the measurement is 130/80 mmHg or greater.Hypertension usually has no symptoms, and many affected individuals do not know they have the condition. However, hypertension is a major risk factor for heart disease, stroke, kidney failure, and eye problems. When blood pressure is elevated, the heart and arteries have to work harder than normal to pump blood through the body. The extra work thickens the muscles of the heart and arteries and hardens or damages artery walls. As a result, the flow of blood and oxygen to the heart and other organs is reduced. Damage to the heart caused by the extra work and a lack of oxygen causes heart disease. In addition, damage to the arteries increases the risk of blood clots that block the flow of blood to the heart, causing a heart attack, or to the brain, causing a type of stroke known as an ischemic stroke. Another type of stroke, called a hemorrhagic stroke, can occur when a weakened blood vessel in the brain bursts. Damage to blood vessels in the kidneys impairs their ability to filter waste and remove fluid, leading to kidney failure. Problems with blood flow in the arteries of the eyes can lead to vision loss.In rare cases, dangerously high blood pressure can cause severe headaches, confusion, shortness of breath, chest pain, or nosebleeds.In about 95 percent of cases, the cause of hypertension is unknown. These cases are classified as essential hypertension. When hypertension results from an underlying condition, such as blood vessel defects that reduce blood flow; kidney disorders, which alter the amount of fluids and salts in the body; or problems with hormone-producing glands called the adrenal glands or the thyroid gland, it is classified as secondary hypertension. Hypertension is a key feature of some rare genetic disorders, including familial hyperaldosteronism, pseudohypoaldosteronism type 2, Liddle syndrome, and tumors known as paragangliomas.

CDC: 2 High blood pressure is a common and dangerous condition. Having high blood pressure means the pressure of the blood in your blood vessels is higher than it should be. But you can take steps to control your blood pressure and lower your risk of heart disease and stroke. About 1 of 3 U.S. adults-or about 75 million people-have high blood pressure.1 Only about half (54%) of these people have their high blood pressure under control.1 Many youth are also being diagnosed with high blood pressure.2 This common condition increases the risk for heart disease and stroke, two of the leading causes of death for Americans.3 Get more quick facts about high blood pressure, or learn more about high blood pressure in the United States. High blood pressure is called the "silent killer" because it often has no warning signs or symptoms, and many people do not know they have it. That's why it is important to check your blood pressure regularly. The good news is that you can take steps to prevent high blood pressure or to control it if your blood pressure is already high.

OMIM®: 57 The Pickering school held that blood pressure has a continuous distribution, that multiple genes and multiple environmental factors determine the level of one's blood pressure just as the determination of stature and intelligence is multifactorial, and that 'essential hypertension' is merely the upper end of the distribution (Pickering, 1978). In this view the person with essential hypertension is one who happens to inherit an aggregate of genes determining hypertension (and also is exposed to exogenous factors that favor hypertension). The Platt school took the view that essential hypertension is a simple mendelian dominant trait (Platt, 1963). McDonough et al. (1964) defended the monogenic idea. See McKusick (1960) and Kurtz and Spence (1993) for reviews. Swales (1985) reviewed the Platt-Pickering controversy as an 'episode in recent medical history.' The Pickering point of view appears to be more consistent with the observations. (145500) (Updated 08-Dec-2022)

Disease Ontology 11 Hypertension: An artery disease characterized by chronic elevated blood pressure in the arteries.

Essential hypertension: A hypertension with no known cause. It is the most common type of hypertension.

UniProtKB/Swiss-Prot: 73 A condition in which blood pressure is consistently higher than normal with no identifiable cause.

Wikipedia 75 Essential hypertension: Essential hypertension (also called primary hypertension, or idiopathic hypertension) is the form of... more...

Hypertension: Hypertension (HTN or HT), also known as high blood pressure (HBP), is a long-term medical condition in... more...

Related Diseases for Hypertension, Essential

Diseases in the Malignant Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Benign Essential Hypertension Benign Secondary Hypertension
Malignant Secondary Hypertension Hypertension Due to Gain-of-Function Mutations in the Mineralocorticoid Receptor

Diseases related to Hypertension, Essential via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3368)
# Related Disease Score Top Affiliating Genes
1 pulmonary hypertension 34.1 PTGIS NOS3 ECE1 AGTR1 AGT
2 renovascular hypertension 33.7 PKD1 NOS3 AGTR1 AGT
3 type 2 diabetes mellitus 33.5 NOS3 MIR155 GNB3 GAS5 CDKN2B-AS1 AGTR1
4 renal hypertension 33.4 NOS3 AGTR1 AGT
5 kidney disease 33.0 PKD2 PKD1 NOS3 CYP3A5 COL4A5 AGTR1
6 diabetes mellitus 32.9 NOS3 MIR155 MEN1 GNB3 CELA2A CDKN2B-AS1
7 chronic kidney disease 32.9 PKD2 PKD1 NOS3 COL4A5 AGTR1 AGT
8 lipoprotein quantitative trait locus 32.8 NOS3 MIR155 GNB3 GAS5 CELA2A CDKN2B-AS1
9 cerebrovascular disease 32.7 MIR155 F12 AGTR1 AGT
10 stroke, ischemic 32.7 PTGIS NOS3 GNB3 CDKN2B-AS1 AGTR1 AGT
11 cardiovascular system disease 32.7 NOS3 MIR155 ECE1 CDKN2B-AS1 AGTR1 AGT
12 myocardial infarction 32.7 PTGIS NOS3 MIR155 GNB3 CDKN2B-AS1 AGTR1
13 autosomal dominant polycystic kidney disease 32.6 PKD2 PKD1 NOS3 COL4A5 AGT
14 congenital hepatic fibrosis 32.5 PKD2 PKD1
15 malignant secondary hypertension 32.4 AGTR1 AGT
16 atherosclerosis susceptibility 32.3 NOS3 CDKN2B-AS1 AGTR1 AGT
17 polycystic kidney disease 1 with or without polycystic liver disease 32.3 PKD2 PKD1 NOS3
18 microvascular complications of diabetes 5 32.2 NOS3 AGTR1 AGT
19 end stage renal disease 32.1 PKD2 PKD1 COL4A5
20 fabry disease 32.1 NOS3 AGTR1 AGT
21 pulmonary edema 32.0 NOS3 AGTR1 AGT
22 polycystic kidney disease 3 with or without polycystic liver disease 31.9 PKD2 PKD1
23 caroli disease 31.9 PKD2 PKD1
24 fibromuscular dysplasia 31.8 AGTR1 AGT
25 orthostatic intolerance 31.6 PKD2 PKD1 NOS3 AGTR1
26 iga glomerulonephritis 31.6 AGTR1 AGT ADD1
27 renal artery disease 31.6 NOS3 AGT
28 aortic aneurysm, familial abdominal, 1 31.5 NOS3 CDKN2B-AS1 AGTR1
29 multicystic dysplastic kidney 31.3 PKD2 PKD1 AGTR1 AGT
30 cerebral palsy 31.3 NOS3 GNB3 AGTR1 AGT ADD1
31 oligohydramnios 31.2 PKD1 AGTR1 AGT
32 diastolic heart failure 31.1 NOS3 AGTR1
33 cerebral arterial disease 30.3 PKD2 PKD1 NOS3 CDKN2B-AS1
34 angioedema, hereditary, 3 30.0 SLC34A1 F12
35 portal hypertension 11.8
36 pre-eclampsia 11.8
37 hypertension and brachydactyly syndrome 11.7
38 intracranial hypertension, idiopathic 11.6
39 ocular hypertension 11.6
40 chronic thromboembolic pulmonary hypertension 11.6
41 pulmonary arterial hypertension associated with portal hypertension 11.6
42 hypertension, diastolic 11.5
43 pseudohypoaldosteronism, type iie 11.5
44 intracranial hypertension 11.5
45 malignant hypertension 11.5
46 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 11.5
47 portal hypertension, noncirrhotic, 1 11.5
48 hyperaldosteronism, familial, type i 11.5
49 heritable pulmonary arterial hypertension 11.4
50 hypertension, essential 3 11.4

Comorbidity relations with Hypertension, Essential via Phenotypic Disease Network (PDN): (show top 50) (show all 295)


Abducens Palsy Acquired Polycythemia
Active Peptic Ulcer Disease Acute Closed-Angle Glaucoma
Acute Conjunctivitis Acute Cystitis
Acute Ethmoiditis Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Pancreatitis Acute Stress Disorder
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Adrenal Gland Disease Age-Related Hearing Loss
Alcohol Use Disorder Allergic Rhinitis
Allergic Urticaria Alopecia, Neurologic Defects, and Endocrinopathy Syndrome
Angina Pectoris Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Atrioventricular Block Atrophic Gastritis
Atypical Depressive Disorder Auditory System Disease
Autonomic Nervous System Disease Basilar Artery Insufficiency
Bipolar Disorder Bleeding Disorder, Platelet-Type, 11
Blepharitis Borderline Glaucoma
Borderline Personality Disorder Brain Cancer
Brain Compression Brain Edema
Branch Retinal Artery Occlusion Bronchitis
Buerger Disease Campylobacteriosis
Cardiac Arrest Central Nervous System Origin Vertigo
Central Retinal Artery Occlusion Central Retinal Vein Occlusion
Cerebral Arteritis Cerebral Atherosclerosis

Graphical network of the top 20 diseases related to Hypertension, Essential:



Diseases related to Hypertension, Essential

Symptoms & Phenotypes for Hypertension, Essential

Human phenotypes related to Hypertension, Essential:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 elevated systolic blood pressure 30 HP:0004421
2 elevated diastolic blood pressure 30 HP:0005117
3 elevated mean arterial pressure 30 HP:0004972

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Cardiovascular Vascular:
elevated systolic blood pressure
elevated diastolic blood pressure
elevated mean arterial pressure

Clinical features from OMIM®:

145500 (Updated 08-Dec-2022)

UMLS symptoms related to Hypertension, Essential:


tremor; angina pectoris; chest pain; edema; equilibration disorder

MGI Mouse Phenotypes related to Hypertension, Essential:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.06 ADD1 AGT AGTR1 CELA2A ECE1 F12
2 homeostasis/metabolism MP:0005376 10.03 ADD1 AGT AGTR1 COL4A5 CYP3A5 DARS2
3 normal MP:0002873 9.97 CYP3A5 ECE1 F12 MEN1 MIR155 NOS3
4 renal/urinary system MP:0005367 9.86 AGT AGTR1 COL4A5 NOS3 PKD1 PKD2
5 cardiovascular system MP:0005385 9.65 AGT AGTR1 CELA2A COL4A5 ECE1 MEN1
6 mortality/aging MP:0010768 9.5 ADD1 AGT AGTR1 COL4A5 CYP3A5 DARS2

Drugs & Therapeutics for Hypertension, Essential

Drugs for Hypertension, Essential (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 905)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Digoxin Approved Phase 4 20830-75-5 3062 2724385 30322
2
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Lymecycline Approved, Investigational Phase 4 992-21-2
5
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
6
Etanercept Approved, Investigational Phase 4 185243-69-0
7
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
8
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
9
Certolizumab pegol Approved Phase 4 428863-50-7
10
Adalimumab Approved, Experimental Phase 4 331731-18-1
11
Evolocumab Approved Phase 4 1256937-27-5
12
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
13
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9 4872
14
Atenolol Approved Phase 4 29122-68-7 2249
15
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
16
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
17
Lacidipine Approved, Investigational Phase 4 103890-78-4 68733 5311217
18
Warfarin Approved Phase 4 81-81-2, 129-06-6 54678486
19
Riociguat Approved Phase 4 625115-55-1 11304743
20
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
21
Dapagliflozin Approved Phase 4 461432-26-8 9887712
22
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
23
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
24
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
25
Thrombin Approved, Investigational Phase 4
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
28
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
29
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
30
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
31
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
32
Promethazine Approved, Investigational Phase 4 60-87-7 4927
33
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
34
Tocopherol Approved, Investigational Phase 4 1406-66-2
35
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294
36
Carteolol Approved Phase 4 51781-06-7 2583
37
Nadolol Approved Phase 4 42200-33-9 39147
38
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
39
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
40
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
41
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
42
Dipivefrin Approved Phase 4 52365-63-6 3105
43
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
44
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
45
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
46
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
47
Mitomycin Approved Phase 4 50-07-7 5746
48
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
49
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
50
Regadenoson Approved, Investigational Phase 4 313348-27-5 22451303 219024

Interventional clinical trials:

(show top 50) (show all 7382)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
2 Phase 4 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Ramiprin Tab. in Essential Hypertension Unknown status NCT00366119 Phase 4 Ramipril
3 A Randomized, Double-blind, Multi-center, Phase Ⅳ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety Between Amlodipine Besylate/Candesartan Cilexetil Combination Tablets and Co-administration of Amlodipine Besylate and Candesartan Cilexetil in Patients With Essential Hypertension Unknown status NCT03231982 Phase 4 Group I;Group II
4 Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension Unknown status NCT01238705 Phase 4 Felodipine add Irbesartan;Felodipine add Metoprolol
5 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
6 Evaluation of Carotid Intima Media Thickness by Treatment of Vascular and Metabolic Factors With Combined Antihypertensive and Hypolipidemic Therapy Unknown status NCT04306627 Phase 4 Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
7 Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue Unknown status NCT02996916 Phase 4 Olmesartan;Amlodipine
8 Antihypertensive Drug Treatment Decisions Based on Home Blood Pressure Monitoring Unknown status NCT00841308 Phase 4
9 Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study Unknown status NCT00716950 Phase 4 valsartan/amlodpine;losartan/amlodpine
10 Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Unknown status NCT00994617 Phase 4 Losartan and hydrochlorothiazide;Hydrochlorothiazide switched over with Losartan at 8 weeks
11 GRK4 Polymorphisms Blood Pressure Response to Candesartan Unknown status NCT01629225 Phase 4 Candesartan
12 Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
13 Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure Unknown status NCT02357615 Phase 4 nifedipine CR tablets (Xin Ran);Adalat
14 Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy Unknown status NCT03226340 Phase 4 S-amlodipine 2.5mg + Chlorthalidone 25mg;S-amlodipine 2.5mg + Telmisartan 40mg
15 Treatment of HYpertension: Morning Versus Evening Unknown status NCT02214498 Phase 4 Enalapril/hydrochlorothiazide;Placebo
16 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
17 Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension: a Multi-center, Open-label, Observational Study Unknown status NCT02641821 Phase 4 Nifedipine GITS
18 Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study Unknown status NCT03809156 Phase 4 Riociguat Oral Product
19 Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Unknown status NCT03053739 Phase 4 Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo
20 Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment Unknown status NCT00483626 Phase 4 oral sildenafil
21 Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial Unknown status NCT03236818 Phase 4 ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
22 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
23 Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4 Spironolactone;Placebo
24 Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic Unknown status NCT04559074 Phase 4 Amlodipine
25 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
26 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
27 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
28 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4 Tadalafil;Vardenafil
29 Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial. Unknown status NCT04353193 Phase 4 Terlipressin;Octreotide
30 An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma Unknown status NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
31 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
32 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
33 Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study Unknown status NCT02338687 Phase 4
34 Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Unknown status NCT01649739 Phase 4 Levitra
35 Phase 4 Study of Medical Therapy Versus Medical Therapy Plus Renal Artery Stenting in Preventing the Progression of Renal Failure in Atherosclerotic Renovascular Disease Unknown status NCT01023373 Phase 4 Medical treatment
36 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
37 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo Unknown status NCT02404779 Phase 4 cisatracurium besilate
38 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
39 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
40 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
41 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
42 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus Unknown status NCT02945982 Phase 4 Entecavir+Carvedilol;Entecavir+Carvedilol+ Fuzheng Huayu
43 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus Unknown status NCT02945956 Phase 4 Entecavir;Entecavir + Fuzheng Huayu
44 Prospective, Interventional Multicentre Study on the Effect of Deepening of Sedation on Intra-abdominal Pressure Unknown status NCT02944292 Phase 4 Propofol
45 Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS) Unknown status NCT02925975 Phase 4 Carvedilol
46 the Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
47 The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension Unknown status NCT02156024 Phase 4 Gastrodia and Uncaria Drink
48 Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep Unknown status NCT02150616 Phase 4 Oxygen;Sham oxygen (room air)
49 A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy Unknown status NCT02920593 Phase 4 Vitamin D3
50 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4

Search NIH Clinical Center for Hypertension, Essential

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acebutolol
Acebutolol Hydrochloride
Amiloride
Amiloride Hydrochloride
Amlodipine
Amlodipine Besylate
Angelica sinensis preparation
Antihypertensives, Other
Atenolol
benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bepridil
Bepridil hydrochloride
Betaxolol
Betaxolol Hydrochloride
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Carteolol
Carteolol Hydrochloride
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
Clonidine
CLONIDINE HCL PWDR
Clonidine Hydrochloride
coenzyme Q10
cyclothiazide
deserpidine
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Doxazosin
Doxazosin Mesylate
eplerenone
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Ethacrynate Sodium
Ethacrynic Acid
Felodipine
Fish Oils
Fosinopril
Fosinopril Sodium
Furosemide
Guanabenz
Guanabenz Acetate
guanadrel
Guanadrel sulfate
Guanethidine
Guanethidine Monosulfate
Guanfacine
Guanfacine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Indapamide
irbesartan
Isradipine
Lisinopril
Losartan
Losartan Potassium
Methyclothiazide
Methyldopa
Methyldopate hydrochloride
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Mibefradil
Mibefradil Dihydrochloride
moexipril
Moexipril hydrochloride
Nadolol
Nicardipine
Nicardipine hydrochloride
Nifedipine
Nisoldipine
Oil of garlic
olmesartan
Olmesartan medoxomil
Penbutolol
Penbutolol Sulfate
Perindopril
Perindopril arginine
Perindopril Erbumine
Pindolol
Polythiazide
Prazosin
Prazosin hydrochloride
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Reserpine
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Terazosin
terazosin hydrochloride
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Triamterene
Trichlormethiazide
valsartan
Verapamil
Verapamil hydrochloride

Cochrane evidence based reviews: hypertension

Genetic Tests for Hypertension, Essential

Genetic tests related to Hypertension, Essential:

# Genetic test Affiliating Genes
1 Essential Hypertension 28
2 Hypertensive Disorder 28

Anatomical Context for Hypertension, Essential

Organs/tissues related to Hypertension, Essential:

MalaCards : Heart, Kidney, Eye, Brain, Endothelial, Lung, Liver

Publications for Hypertension, Essential

Articles related to Hypertension, Essential:

(show top 50) (show all 51547)
# Title Authors PMID Year
1
Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. 53 62 57 5
8021009 1994
2
Molecular basis of human hypertension: role of angiotensinogen. 53 62 57 5
1394429 1992
3
Splicing mutation of the prostacyclin synthase gene in a family associated with hypertension. 62 57 5
12372404 2002
4
Association of a human G-protein beta3 subunit variant with hypertension. 62 57 5
9425898 1998
5
Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. 57 5
12566389 2003
6
Natural selection and population history in the human angiotensinogen gene (AGT): 736 complete AGT sequences in chromosomes from around the world. 53 62 5
15077204 2004
7
A1166C variant of angiotensin II type 1 receptor gene is associated with severe hypertension in pregnancy independently of T235 variant of angiotensinogen gene. 53 62 5
15042429 2004
8
Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. 53 62 5
10024330 1999
9
Angiotensinogen gene and hypertension in Chinese. 53 62 5
9421481 1998
10
Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. 53 62 5
9149697 1997
11
Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. 53 62 5
9084931 1997
12
Selectively enhanced cellular signaling by Gi proteins in essential hypertension. G alpha i2, G alpha i3, G beta 1, and G beta 2 are not mutated. 53 62 57
8888689 1996
13
Transgenic mice with -6A haplotype of the human angiotensinogen gene have increased blood pressure compared with -6G haplotype. 62 5
20978123 2010
14
Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. 62 57
18669922 2008
15
A high-density admixture scan in 1,670 African Americans with hypertension. 62 57
18020707 2007
16
Multiple genes for essential-hypertension susceptibility on chromosome 1q. 62 57
17236131 2007
17
Implication of chromosome 18 in hypertension by sibling pair and association analyses: putative involvement of the RKHD2 gene. 62 57
17015768 2006
18
Linkage analysis using co-phenotypes in the BRIGHT study reveals novel potential susceptibility loci for hypertension. 62 57
16826522 2006
19
Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. 62 57
16216958 2005
20
Admixture mapping for hypertension loci with genome-scan markers. 62 57
15665825 2005
21
Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. 62 57
15611369 2005
22
Sibpair studies implicate chromosome 18 in essential hypertension. 62 57
15054836 2004
23
Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. 62 57
12761042 2003
24
A new essential hypertension susceptibility locus on chromosome 2p24-p25, detected by genomewide search. 62 57
12228842 2002
25
Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension. 62 57
11857741 2002
26
Chromosome 17 and the inducible nitric oxide synthase gene in human essential hypertension. 62 57
11702222 2001
27
Molecular mechanisms of human hypertension. 62 57
11239411 2001
28
Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. 62 57
10406815 1999
29
An extreme-sib-pair genome scan for genes regulating blood pressure. 62 57
10330357 1999
30
Associations of angiotensinogen gene mutations with hypertension and myocardial infarction in a gulf population. 62 5
9831339 1998
31
Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. 62 5
9894356 1998
32
Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. 62 57
9328471 1997
33
A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist. 62 57
9329963 1997
34
Association of the renin gene polymorphism with essential hypertension in a Chinese population. 62 57
9237498 1997
35
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. 62 57
9109431 1997
36
A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. 62 5
9120024 1997
37
Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. 62 57
8528250 1996
38
Variation at the M235T locus of the angiotensinogen gene and essential hypertension: a population-based case-control study from Rochester, Minnesota. 62 5
7649545 1995
39
Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. 62 57
7635969 1995
40
Linkage of the angiotensinogen gene to essential hypertension. 62 57
8177268 1994
41
A molecular variant of angiotensinogen associated with preeclampsia. 62 5
8513325 1993
42
Rapid detection of the hypertension-associated Met235-->Thr allele of the human angiotensinogen gene. 62 5
8518804 1993
43
Dysfunction of placental glucocorticoid barrier: link between fetal environment and adult hypertension? 62 57
8094124 1993
44
Glucocorticoid exposure in utero: new model for adult hypertension. 62 57
8094115 1993
45
Genetics of essential hypertension. 62 57
8420305 1993
46
Baroreflex sensitivity and heredity in essential hypertension. 62 57
1735146 1992
47
Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. 62 57
1655275 1991
48
Genetic and environmental explanations for the distribution of sodium-lithium countertransport in pedigrees from Rochester, MN. 62 57
2035530 1991
49
Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. 62 57
2017226 1991
50
Exclusion of the Na(+)-H+ antiporter as a candidate gene in human essential hypertension. 62 57
1846121 1991

Variations for Hypertension, Essential

ClinVar genetic disease variations for Hypertension, Essential:

5 (show all 39)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 UMOD NM_003361.3(UMOD):c.-1746T>C SNV Association
219224 rs13333226 GRCh37: 16:20365654-20365654
GRCh38: 16:20354332-20354332
2 overlap with 4 genes GRCh37/hg19 15q11.2(chr15:22765628-23300287) CN LOSS Pathogenic
523249 GRCh37: 15:22765628-23300287
GRCh38:
3 F12, SLC34A1 NM_000505.4(F12):c.983C>G (p.Thr328Arg) SNV Pathogenic
1170 rs118204456 GRCh37: 5:176831232-176831232
GRCh38: 5:177404231-177404231
4 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn) SNV Pathogenic
633592 rs1352544800 GRCh37: 1:15789885-15789885
GRCh38: 1:15463390-15463390
5 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met) SNV Pathogenic
633593 rs558493952 GRCh37: 1:15789253-15789253
GRCh38: 1:15462758-15462758
6 CELA2A NM_033440.3(CELA2A):c.639+1G>C SNV Pathogenic
633594 rs752331004 GRCh37: 1:15792640-15792640
GRCh38: 1:15466145-15466145
7 MTX2 NM_006554.5(MTX2):c.295_296del (p.Ser98_Leu99insTer) MICROSAT Pathogenic
827676 rs768727228 GRCh37: 2:177193027-177193028
GRCh38: 2:176328299-176328300
8 PKD2 NM_000297.4(PKD2):c.357_364delinsTAGGACG (p.Pro120fs) INDEL Pathogenic
373955 rs1057518797 GRCh37: 4:88929242-88929249
GRCh38: 4:88008090-88008097
9 PKD1 NM_001009944.3(PKD1):c.3520C>T (p.Gln1174Ter) SNV Pathogenic
374102 rs1057518899 GRCh37: 16:2161648-2161648
GRCh38: 16:2111647-2111647
10 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met) SNV Pathogenic
633595 rs372947070 GRCh37: 1:15788135-15788135
GRCh38: 1:15461640-15461640
11 PTGIS NM_000961.4(PTGIS):c.1358+2T>C SNV Pathogenic
7864 rs13306026 GRCh37: 20:48127563-48127563
GRCh38: 20:49511026-49511026
12 MEN1 NM_001370259.2(MEN1):c.654+1del DEL Pathogenic
374107 rs1057518903 GRCh37: 11:64575362-64575362
GRCh38: 11:64807890-64807890
13 PKD1 NM_001009944.3(PKD1):c.8311G>A (p.Glu2771Lys) SNV Pathogenic
374097 rs1057518897 GRCh37: 16:2153747-2153747
GRCh38: 16:2103746-2103746
14 COL4A5 NM_033380.3(COL4A5):c.1871G>A (p.Gly624Asp) SNV Pathogenic
24455 rs104886142 GRCh37: X:107842023-107842023
GRCh38: X:108598793-108598793
15 DARS2 NM_018122.5(DARS2):c.228-21_228-20delinsC INDEL Pathogenic
1057 rs1553201258 GRCh37: 1:173797450-173797451
GRCh38: 1:173828312-173828313
16 DARS2 NM_018122.5(DARS2):c.492+2T>C SNV Pathogenic
1062 rs142433332 GRCh37: 1:173800770-173800770
GRCh38: 1:173831632-173831632
17 GNB3, CDCA3 NM_002075.4(GNB3):c.825C>T (p.Ser275_Val276=) SNV Risk Factor
226004 rs5443 GRCh37: 12:6954875-6954875
GRCh38: 12:6845711-6845711
18 AGT NM_001382817.3(AGT):c.-30-3273G>A SNV Risk Factor
296090 rs5051 GRCh37: 1:230849872-230849872
GRCh38: 1:230714126-230714126
19 LOC106627981, GBA1 NM_000157.4(GBA1):c.1093G>A (p.Glu365Lys) SNV Risk Factor
199044 rs2230288 GRCh37: 1:155206167-155206167
GRCh38: 1:155236376-155236376
20 INF2 NM_022489.4(INF2):c.658G>A (p.Glu220Lys) SNV Likely Pathogenic
523533 rs530391015 GRCh37: 14:105169782-105169782
GRCh38: 14:104703445-104703445
21 ECE1 NM_001113348.2(ECE1):c.4-596C>A SNV Risk Factor
9134 GRCh37: 1:21617245-21617245
GRCh38: 1:21290752-21290752
22 ECE1 NM_001113348.2(ECE1):c.4-1097T>G SNV Risk Factor
9135 GRCh37: 1:21617746-21617746
GRCh38: 1:21291253-21291253
23 ADD1 NM_001354761.2(ADD1):c.1378G>T (p.Gly460Trp) SNV Risk Factor
18274 rs4961 GRCh37: 4:2906707-2906707
GRCh38: 4:2904980-2904980
24 AGTR1 NM_000685.5(AGTR1):c.599dup (p.Asn200fs) DUP Likely Pathogenic
1179033 GRCh37: 3:148459416-148459417
GRCh38: 3:148741629-148741630
25 PKD1-AS1, PKD1 NM_001009944.3(PKD1):c.11524T>C (p.Trp3842Arg) SNV Likely Pathogenic
374187 rs1057518959 GRCh37: 16:2141795-2141795
GRCh38: 16:2091794-2091794
26 AGTR1 NM_000685.5(AGTR1):c.*86A>C SNV Risk Factor
18065 rs5186 GRCh37: 3:148459988-148459988
GRCh38: 3:148742201-148742201
27 AGT NM_000029.4(AGT):c.803T>C (p.Met268Thr) SNV Risk Factor
Benign
18068 rs699 GRCh37: 1:230845794-230845794
GRCh38: 1:230710048-230710048
28 PKD1 NM_001009944.3(PKD1):c.9185T>A (p.Val3062Asp) SNV Likely Pathogenic
374044 rs1057518856 GRCh37: 16:2152398-2152398
GRCh38: 16:2102397-2102397
29 COL4A4 NM_000092.5(COL4A4):c.2320G>C (p.Gly774Arg) SNV Likely Pathogenic
242442 rs569681869 GRCh37: 2:227924184-227924184
GRCh38: 2:227059468-227059468
30 COL4A4 NM_000092.5(COL4A4):c.4394G>A (p.Gly1465Asp) SNV Likely Pathogenic
523324 rs533297350 GRCh37: 2:227875157-227875157
GRCh38: 2:227010441-227010441
31 MYH9 NM_002473.6(MYH9):c.4271A>G (p.Asp1424Gly) SNV Likely Pathogenic
523453 rs867593888 GRCh37: 22:36688105-36688105
GRCh38: 22:36292059-36292059
32 CYP3A5, ZSCAN25 NM_000777.5(CYP3A5):c.219-237A>G SNV Risk Factor
5066 rs776746 GRCh37: 7:99270539-99270539
GRCh38: 7:99672916-99672916
33 NOS3 NM_000603.5(NOS3):c.284C>T (p.Thr95Ile) SNV Uncertain Significance
931540 rs1802424536 GRCh37: 7:150693505-150693505
GRCh38: 7:150996417-150996417
34 PTGIS NM_000961.4(PTGIS):c.283G>A (p.Asp95Asn) SNV Uncertain Significance
1033155 rs199740067 GRCh37: 20:48164472-48164472
GRCh38: 20:49547935-49547935
35 COL4A4 NM_000092.5(COL4A4):c.4217-15T>C SNV Uncertain Significance
255039 rs200926310 GRCh37: 2:227877028-227877028
GRCh38: 2:227012312-227012312
36 COL4A4 NM_000092.5(COL4A4):c.3055G>C (p.Glu1019Gln) SNV Uncertain Significance
374041 rs1057518854 GRCh37: 2:227915788-227915788
GRCh38: 2:227051072-227051072
37 KSR2 NM_173598.6(KSR2):c.2512C>T (p.Arg838Cys) SNV Uncertain Significance
1338787 GRCh37: 12:117914339-117914339
GRCh38: 12:117476534-117476534
38 PRKAG2 NM_016203.4(PRKAG2):c.590C>G (p.Pro197Arg) SNV Uncertain Significance
374128 rs368637364 GRCh37: 7:151372600-151372600
GRCh38: 7:151675514-151675514
39 CYP3A5, ZSCAN25 NM_000777.5(CYP3A5):c.1165C>T (p.Pro389Ser) SNV Not Provided
585032 rs765108001 GRCh37: 7:99250264-99250264
GRCh38: 7:99652641-99652641

Copy number variations for Hypertension, Essential from CNVD:

6 (show all 17)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 71427 12 69818942 132349534 Copy number Hypertension
2 109399 17 25800000 31800000 Gain Hypertension
3 112710 17 40930407 78774742 Copy number Hypertension
4 137134 2 138750000 144750000 Deletion ARHGAP15 Hypertension
5 137138 2 138750000 144750000 Deletion GTDC1 Hypertension
6 137142 2 138750000 144750000 Deletion HNMT Hypertension
7 137146 2 138750000 144750000 Deletion KYNU Hypertension
8 137150 2 138750000 144750000 Deletion Hypertension
9 137154 2 138750000 144750000 Deletion LRP1B Hypertension
10 137158 2 138750000 144750000 Deletion NXPH2 Hypertension
11 137162 2 138750000 144750000 Deletion SPOPL Hypertension
12 139337 2 179004449 242951149 Copy number Hypertension
13 195355 5 150157836 180857866 Copy number Hypertension
14 195375 5 150183562 180857866 Copy number Hypertension
15 210789 6 31416574 170899992 Copy number Hypertension
16 211339 6 32582950 170899992 Copy number Hypertension
17 211385 6 32609209 170899992 Copy number Hypertension

Expression for Hypertension, Essential

LifeMap Discovery
Genes differentially expressed in tissues of Hypertension, Essential patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 NBDY negative regulator of P-body association Blood + 3.27 0.005
Search GEO for disease gene expression data for Hypertension, Essential.

Pathways for Hypertension, Essential

Pathways related to Hypertension, Essential according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 NOS3 GNB3 AGTR1 AGT
2
Show member pathways
11.31 NOS3 F12 AGTR1 AGT
3 11.29 NOS3 GNB3 ECE1
4 10.25 F12 AGTR1 AGT

GO Terms for Hypertension, Essential

Cellular components related to Hypertension, Essential according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cation channel complex GO:0034703 9.26 PKD2 PKD1
2 polycystin complex GO:0002133 8.92 PKD2 PKD1

Biological processes related to Hypertension, Essential according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cytosolic calcium ion concentration GO:0007204 10.14 AGT AGTR1 PKD1 PKD2
2 placenta blood vessel development GO:0060674 9.88 PKD2 PKD1
3 positive regulation of CoA-transferase activity GO:1905920 9.87 AGTR1 AGT
4 cytoplasmic sequestering of transcription factor GO:0042994 9.86 PKD2 PKD1
5 response to fluid shear stress GO:0034405 9.85 PKD1 NOS3
6 positive regulation of NAD(P)H oxidase activity GO:0033864 9.83 AGTR1 AGT
7 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.81 NOS3 ECE1
8 mesonephric duct development GO:0072177 9.8 PKD2 PKD1
9 blood vessel diameter maintenance GO:0097746 9.77 NOS3 AGTR1 AGT
10 mesonephric tubule development GO:0072164 9.76 PKD1 PKD2
11 metanephric ascending thin limb development GO:0072218 9.73 PKD2 PKD1
12 regulation of renal sodium excretion GO:0035813 9.71 AGTR1 AGT
13 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.65 AGTR1 AGT
14 renin-angiotensin regulation of aldosterone production GO:0002018 9.62 AGT AGTR1
15 maintenance of blood vessel diameter homeostasis by renin-angiotensin GO:0002034 9.56 AGT AGTR1
16 cell-cell signaling by wnt GO:0198738 9.46 PKD2 PKD1
17 regulation of vasoconstriction GO:0019229 9.43 ECE1 AGTR1 AGT
18 kidney development GO:0001822 9.28 SLC34A1 PKD2 PKD1 AGTR1 AGT

Sources for Hypertension, Essential

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....